Singapore Markets close in 6 hrs 44 mins

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
624.52-23.91 (-3.69%)
At close: 4:00PM EDT

632.20 +7.68 (1.23%)
After hours: 7:54PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close648.43
Bid628.00 x 800
Ask630.00 x 3100
Day's range624.00 - 660.00
52-week range271.37 - 664.64
Avg. volume1,271,568
Market cap64.073B
Beta (5Y monthly)0.57
PE ratio (TTM)31.37
EPS (TTM)19.91
Earnings date03 Nov 2020 - 09 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est643.83
  • Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates

    Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates

    Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.

  • Reuters

    Regeneron profit beats, expects early results from COVID-19 trials in September

    Regeneron is among several drugmakers racing to develop a treatment for the novel coronavirus and earlier this week said its experimental COVID-19 antibody drug combination, REGN-COV2, prevented and treated the disease in rhesus macaques and hamsters. Continued lockdowns to curb the spread of the coronavirus have prompted patients to reschedule their hospital visits, weighing on sales of physician-administered drugs such as Regeneron's blockbuster drug Eylea. U.S. sales of Eylea, approved for treating wet age-related macular degeneration, fell to $1.11 billion from $1.16 billion, but came in above Wall Street estimates of $1.06 billion, according to brokerage Piper Sandler.

  • Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

    Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates

    Regeneron (REGN) delivered earnings and revenue surprises of 14.93% and 9.05%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?